The second quarter of 2014 has come and gone, which means that we are now already half way through 2014. The five-year bull market has managed to continue making its gains. The…
The short interest data for the first two weeks of June show that short interest was higher in almost all our go-to list of defensive high-yield stocks that are not utilities.
ThinkstockThe short interest data for the final two weeks of May have been released, and the results are somewhat surprising when it comes to the top high-yield safe dividends we follow. Some…
Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at one stage or another and that could be the next takeover targets.
24/7 Wall St. wanted to look at the leaders and laggards in the Dow Jones Industrial Average. It turns out that as of Friday's closing bell, seven of the 30 Dow stocks…
thinkstockMay 29, 2014: Markets opened higher on Thursday following reports that U.S. GDP contracted by 1% in the first quarter and that new claims for jobless benefits fell to 300,000. Pending home…
Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance is that Pfizer may now simply be having an identity crisis.
thinkstockMay 8, 2014: Markets opened lower on Thursday and posted solid gains on a good report on new claims for jobless benefits. Momentum stocks lost their get-up-and-go in the afternoon, though, and…
These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, May 8, 2014. They include Chevron, Exxon, FedEx, Merck, Tesla, Twitter, Disney and Yelp.
thinkstockMay 6, 2014: Markets opened lower on Monday and sank slowly and surely for the rest of the day. The dollar weakened against the yen overnight removing some enthusiasm for risk in…
Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced that it had sold the business to Germany-based Bayer for $14.2 billion.
This past week brought yet another swing taking the Dow Jones Industrial Average to within 30 points or so of an all-time record high. 24/7 Wall St, wanted to review the four…
Endocyte and Merck have terminated their joint late-stage study of an ovarian cancer treatment after the trials failed to show results. Endocyte expressed surprise at the recommendation to halt the trial.
Paul Ausick These are the top analyst upgrades, downgrades and initiations from Wall Street on Wednesday, April 30, 2014. They include ARM Holdings, Coach, Merck, Netflix, Sprint, 3D Systems and Twitter.
thinkstockApril 29, 2014: Markets opened higher on Tuesday getting a boost from energy and biotech stocks right at the start of trading. Economic data was both sparse and not supportive, with the…
